首页|托法替尼中间体的合成工艺改进

托法替尼中间体的合成工艺改进

扫码查看
以丙二腈为起始原料,与溴代乙醛缩二乙醇(2)发生α-烷基化反应,后经硫脲环合、脱保护、环合、酸化、脱除巯基、Sandmeyer氯代等反应,得到托法替尼中间体,4-氯-7H-吡咯并[2,3-d]嘧啶(1),总收率49%(以2计),纯度99.10%.该工艺有3点创新:①将巯基化合物成盐,直接从反应溶剂乙醇中析出,克服了巯基化合物难以纯化的技术难点,以较高收率(85%)制得4,6-二氨基-5-(2,2-二乙氧基乙基)嘧啶-2-硫醇钾盐(4);②一锅三步实现盐酸存在下的脱保护、环合、酸化反应,得到4-氨基-7H-吡咯[2,3-d]嘧啶-2-硫醇(5),简化了工序;③成功革除了三氯氧磷、2-甲基-3,3-二氯丙烯腈、2-氯乙醛等有毒试剂的使用,工艺更安全,尤其是三氯氧磷的革除大幅减少了三废,绿色环保.优化后的工艺原料经济易得、反应条件温和、操作简便、收率提高,适合工业化生产.
Improved Synthetic Process of an Intermediate of Tofacitinib
An improved synthetic process of the intermediate of tofacitinib,4-chloro-7H-pyrrolo[2,3-d]-pyrimidine(1),was described in this paper.Started from malononitrile,the desired product 1 was synthesized via a-alkylation with bromoacetaldehyde diethyl acetal(2),cyclization with thiourea,deprotection,cyclization,acidification,removal of the thiol group,as well as Sandmeyer chlorination,with an overall yield of 49%(based on 2)and a purity of 99.10%.The improved process had three apparent advantages compared with previously reported procedures,including:① direct precipitation of the potassium 4,6-diamino-5-(2,2-diethoxyethyl)pyrimidine-2-thiolate(4),from the reaction solvent ethanol as a salt with a high yield of 85%,overcoming the technical difficulties in purifying the thiol compound;② preparation of the 4-amino-7H-pyrrolo[2,3-d]pyrimidine-2-thiol(5)via a one-pot sequential three-step reaction of deprotection,cyclization,and acidification in the presence of hydrochloric acid,simplifying the process;③ elimination toxic reagents such as phosphorus oxychloride,2-methyl-3,3-dichloroacrylonitrile,and 2-chloroacetaldehyde,which ensured process safety and improved environmental friendliness,especially the elimination of phosphorus oxychloride.All the raw materials and reagents used in the improved syntheses are inexpensive and readily available,and the operation is simple with mild conditions and high yield,which is suitable for industrial production.

JAK inhibitortofacitinibintermediate4-chloro-7H-pyrrolo[2,3-d]pyrimidineprocess improvement

朱俊、孙缜、张耀华、喻婕、赵建宏

展开 >

华东理工大学药学院,上海 200237

上海医药集团股份有限公司,上海 200020

JAK抑制剂 托法替尼 中间体 4-氯-7H-吡咯并[2,3-d]嘧啶 工艺改进

2024

中国医药工业杂志
上海医药工业研究院,中国化学制药工业协会

中国医药工业杂志

CSTPCD
影响因子:0.487
ISSN:1001-8255
年,卷(期):2024.55(1)
  • 12